Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure

NCT05913271 is registered in ClinicalTrials.gov with Yi Han as lead sponsor.

NCT NCT05913271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure
Lead sponsor
Yi Han
Phase
Observational
Overall status
Unknown status
Start date
May 30, 2023
Completion date
May 30, 2025
Enrollment
352 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, heart failure, levosimendan, safety